Skinvisible Announces Canadian License Agreement for DermSafe

Unique hand sanitizer lotion that kills H1N1 without alcohol now available

Las Vegas, Nevada - December 9th, 2009 - Skinvisible, Inc. (SKVI:OTCBB) and Alto Pharmaceuticals (www.altopharma.com), a dermatology-focused company based in Toronto, announced today they have entered into a license agreement for DermSafe®, Skinvisible's antimicrobial hand sanitizer lotion that recently completed clinical studies proving it kills the H1N1 virus. Under the terms of the agreement, Alto will pay Skinvisible an upfront license fee for the exclusive manufacturing and the commercial / professional use marketing rights for DermSafe in Canada. Skinvisible will also receive a royalty from product sales.

"Alto Pharmaceuticals has an experienced team with strong pharmaceutical, regulatory, sales and management skills. Their CEO, Joan Chypyha, is the past General Manager of Barrier Therapeutics, (Canada) Inc. Alto's sales team has extensive knowledge of the Canadian pharmaceutical market and is able to leverage their decades of experience and contacts to make DermSafe's introduction into Canada a great success." said Terry Howlett, President and CEO of Skinvisible. "They will initially be focused on the commercial sale of DermSafe to schools, the military, businesses and other commercial and professional establishments that are looking for a unique hand sanitizer made without alcohol."

Unlike most hand sanitizers, DermSafe does not contain alcohol and therefore is non-drying to the skin. Many schools, penitentiaries and other groups with safety concerns have discontinued the use of alcohol-based hand sanitizers. The active ingredient in DermSafe is chlorhexidine gluconate, an ingredient approved by Health Canada under the Human Use Antiseptic Drugs Monograph. This ingredient has been safely used in hospitals worldwide as a pre-surgical scrub as well as in dental applications.

This license agreement is the second DermSafe agreement signed by Skinvisible. The DermSafe licensee, Mayquest Pharmaceuticals, based in Singapore, recently received approval to import DermSafe to Singapore and will commence commercial / professional sales in January 2010. Mayquest Pharmaceuticals has licensed the rights for DermSafe for five countries in Southeast Asia.

Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives and reduce irritation. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants.   www.invisicare.com

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare.   www.skinvisible.com

Alto Pharmaceuticals is focused on the development and commercialization of unique products for maintaining a healthy lifestyle and improving quality of life. Alto's areas of interest include Dermatology, Women's Health and Wound Care and the company is dedicated to bringing physicians, patients and consumers unique pharmaceutical products and devices.   www.altopharma.com

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending October 31, 2009).